Business Update
MethylGene picks multi-targeted kinase as clinical candidate in cancer tumors, angiogenesis
Published in Medical Letter on the CDC and FDA, January 14th, 2007
MGCD265 targets the c-MET, VEGFR1, VEGFR2, VEGFR3, Tie-2 and Ron receptor tyrosine kinases, which appear to play key roles in tumor development and blood vessel formation (angiogenesis) and tumor survival.
The c-MET target has become one of intense scientific and pharmaceutical interest because of its direct involvement in tumor cell survival and angiogenesis. In addition, there is strong evidence that c-MET levels are associated with poor prognosis in several major solid tumor types.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Cancer Vaccines
Data from University of Pittsburgh, Pittsburgh Cancer Institute advance knowledge in cancer vaccines - Alzheimer Disease
Memory Pharmaceuticals reports U.S. FDA release of clinical hold on Alzheimer drug MEM 3454 - Anemia
Data show efficacy of extended dosing of Aranesp in treatment of chemotherapy-induced anemia - Anemia
Phase II data show promise of Aranesp treatment for anemia of cancer - Business & Finance
Adolor discontinues sales force and reports other selected work force reductions - Business & Finance
Migenix updates celgosivir hepatitis C study data, reports Q2 2007 $3.7 million loss - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
